Oxford Nanopore Reports Strong H2 Growth, Sequencing Volume Up 65% YoY

Oxford Nanopore Technologies (OXB) delivered a standout performance in the second half of 2025, reporting a 65% year-over-year increase in sequencing volume, reflecting strong adoption of its nanopore-based platforms across academic, clinical, and biopharmaceutical sectors. Total revenue for the period reached £184 million, up from £112 million in the same period the prior year, demonstrating accelerating market penetration and expanding customer base. The company attributed the growth to increased use of its MinION and PromethION systems in infectious disease surveillance, oncology research, and long-read sequencing applications. The company’s operational efficiency improved significantly, with gross margin expanding to 58%, up from 52% in H2 2024. This improvement was driven by higher volume throughput and cost optimizations in consumables production. Oxford Nanopore also reported a 42% increase in active customers, including new institutional partnerships in Europe and the U.S., signaling broadening market acceptance. The financial performance comes amid rising global interest in real-time, portable genomic analysis, particularly in public health and personalized medicine. The company’s recent collaboration with the UK’s National Health Service (NHS) on pathogen monitoring and its entry into the Chinese market highlight strategic market expansion efforts. These initiatives are expected to contribute to sustained revenue growth, with management guiding for full-year 2026 revenue to exceed £400 million. The results have implications for biotech and healthcare equities, particularly in the healthcare sector (XLV), where innovation in diagnostics is a key growth driver. The performance also supports continued investor interest in disruptive life sciences technologies. As sequencing costs decline and applications widen, Oxford Nanopore’s scalable platform is well-positioned to capture further market share.